InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,595.76
(
0.75%
)
US TECH 100
18,897.20
(
0.81%
)
Dow Jones
41,096.77
(
0.58%
)
Brent Oil
71.94
(
2.01%
)
Bitcoin
58,174.18
(
1.45%
)
Post# of 203990
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Dspetry

Send PM Follow Ignore
Followers 113
Posts 11274
Boards Moderated 2
Alias Born 02/06/2005

Dspetry

Re: lmf1264 post# 194208

Friday, 03/27/2009 2:00:40 PM

Friday, March 27, 2009 2:00:40 PM

Post# of 203990
Charles Wambebe, chief executive officer of the International Biomedical Research Institute in Abuja, Nigeria, and former director-general of NIPRD, says: "The development is a good one for the country. Now sickle cell sufferers in Nigeria can access the drug cheaply".

"Seeing that Xechem failed to live up to their expectations, let the status quo remain — that is, NIPRD producing the drug for Nigerians. After all Xechem did not add any value to the whole process," he told SciDev.Net.

Nice going Swift, you POS !!!
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up